#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Factor VIII deficiency Neuropathic arthropathy Anti-myelin-associated glycoprotein antibodies positive Glomerulonephritis minimal lesion Familial haemophagocytic lymphohistiocytosis Pneumonia Squamous cell carcinoma of the hypopharynx Adenocarcinoma gastric Acquired ATTR amyloidosis Kidney transplant rejection Oesophageal squamous cell carcinoma stage II Hepato-lenticular degeneration Cytokine release syndrome Congenital cystic kidney disease Anti-neutrophil cytoplasmic antibody positive vasculitis More trials…

    Learn about Rare Diseases

    Nephrotic syndrome – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Basic Information Mucopolysaccharidosis – Trials in Disease Testicular leiomyosarcoma – Diagnostics Inclusion body myositis X-linked lymphoproliferative syndrome – Diagnostics Acquired haemophilia – Diagnostics Marginal zone lymphoma – Basic Information Pituitary-dependent Cushing’s syndrome – Treatment Progressive supranuclear palsy More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Asciminib Mezigdomide Ondansetron Mexiletine Hydrochloride F770/05 METAMIZOLE SODIUM Ethambutol M-(18F)-Fluorobenzylguanidine Ly3454738 VRDN-003 Mitazalimab Adrc001 Amitriptyline Atogepant Interferon Beta-1A Csm-Gw Arginine Human Cancellous Bone Imipramine Hydrochloride Magnesium Chloride More therapies…

    Learn about Your Condition

    Alveolar rhabdomyosarcoma Neuroendocrine tumour Thyroidectomy Migraine HER2 negative breast cancer Spinal osteoarthritis High-grade B-cell lymphoma Osteoarthritis Hip arthroplasty Hypersomnia Brain cancer metastatic Acquired haemophilia Respiratory failure Behcet's syndrome Angiosarcoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study on the Effectiveness of Talquetamab and Teclistamab in First-Line Treatment for Transplant-Eligible Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Talquetamab
    • Teclistamab
    • Bortezomib
    Denmark Estonia Norway

  • Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Montelukast Sodium
    • Talquetamab
    • Dexamethasone Acetate
    France

  • Study on Venetoclax and Dexamethasone for Patients with Relapsed and Refractory Multiple Myeloma with Translocation (11;14)

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Pneumococcal Polysaccharide Serotype 17F
    • Pneumococcal Polysaccharide Serotype 2
    • Pneumococcal Polysaccharide Serotype 20
    Denmark

  • Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Elranatamab
    • Human Normal Immunoglobulin
    • Lenalidomide
    Austria Belgium Czechia Finland France Germany +8

  • Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Ciltacabtagene Autoleucel
    • Dexamethasone Ph. Eur.
    • Bortezomib
    Austria Belgium Czechia Denmark Finland France +10

  • Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone Base
    • Dexamethasone Sodium Phosphate Ph. Eur.
    • Isatuximab
    Czechia Finland France Greece Italy Spain +1
Previous Page
1 … 18 19 20 21 22 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!